VitusCare Secures $3 Million for Dialysis Expansion
VitusCare, a prominent dialysis care provider, has successfully secured $3 million through a Series B funding round, featuring contributions from Liberty Ridge Capital, a Singapore-based healthcare growth equity firm, alongside HDFC Bank, Equentis, NAFA Capital Advisors, and existing investors such as 1Crowd and 3i Partners, in addition to various angel investors.
Headquartered in Gurugram, the company previously obtained $2.7 million during a Series A round led by Tomorrow Capital in April 2024 and Rs 10.83 crore in a seed round back in 2019. The newly raised funds will be utilised for expanding the network of dialysis centres, advancing technology, enhancing workforce training, and supporting international growth, as stated in a press release by VitusCare.
This funding comes as VitusCare celebrates a remarkable increase in revenue, nearly tripling since the last funding round in 2024. The company’s network has experienced significant growth, expanding from 22 to over 60 dialysis centres across nine states and more than 50 cities. To date, VitusCare has provided treatment for over 35,000 patients and has conducted surpassing 8 lakh dialysis sessions. Additionally, the workforce has expanded from 110 to 300 employees.
According to the company, it achieved positive corporate EBITDA for FY26, driven by a quicker path to breakeven at newly opened centres and same-centre growth exceeding 30%. Founded in 2017 by Prabhat Shrivastava, VitusCare operates with a capital-efficient ‘shop-in-shop’ model. This model enables partnerships with existing hospitals to deliver specialised dialysis services instead of establishing standalone facilities.
The company’s ambition is to grow its network to over 100 centres by the conclusion of FY27 while also exploring opportunities in selective Asian markets. VitusCare is in the process of developing AI-native business models aimed at enhancing healthcare delivery and plans to establish a Technician Academy for training dialysis professionals.
VitusCare competes with other players in the market such as NephroPlus, Apex Kidney Care, DCDC Kidney Care, 7Med, and Rahi Care. Under the shop-in-shop model, dialysis providers furnish equipment, skilled medical professionals, technology, and operational support while leveraging hospitals’ pre-existing infrastructure, thereby enabling expansion with diminished capital expenditure, particularly in Tier II and III cities. Further competitors in this sector include DCDC Kidney Care, which secured Rs 150 crore from the Temasek-backed ABC Impact in March 2025, and The Renal Project, which acquired $1.3 million during a pre-seed round led by JITO Angel Network in September 2026.
